<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577472</url>
  </required_header>
  <id_info>
    <org_study_id>CANTAPOR_2012</org_study_id>
    <nct_id>NCT01577472</nct_id>
  </id_info>
  <brief_title>Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol</brief_title>
  <acronym>CANTAPOR</acronym>
  <official_title>Prospective Randomized Phase IV Study Comparing the Effect of Adding Clomiphencitrate Versus Placebo to a High Dose Versus a Minimal Dose GnRH Antagonist Protocol on the Number of Oocytes Collected From Women That Are Poor Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the oocyte yield of infertile women with suspected or&#xD;
      known poor ovarian reserve (POR) undergoing a GnRH antagonist protocol for IVF with Merional®&#xD;
      starting either with a low (150 IU) or a high dose (450 IU) and adding 100mg of CC&#xD;
      (Serophene®) in the early follicular phase of the stimulation (day 3 to 7). To date no RCT&#xD;
      has been conducted to compare the reproductive outcome of patients with POR as defined by the&#xD;
      ESHRE Bologna criteria after controlled ovarian hyperstimulation with HMG in an GnRH&#xD;
      antagonist protocol using low doses versus high doses of HMG and adding CC versus placebo. We&#xD;
      hypothesize that adding 100 mg of CC on day 3-7 to a HMG antagonist protocol will lead to an&#xD;
      additional increment of endogenous GT thus increasing the oocytes yield after controlled&#xD;
      ovarian stimulation due to higher endogenous gonadotropin secretion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">November 14, 2017</completion_date>
  <primary_completion_date type="Actual">November 14, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of collected oocytes</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Female Infertility</condition>
  <condition>Ovarian Insufficiency</condition>
  <arm_group>
    <arm_group_label>High Dose Clomiphencitrat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>450 IU Merional® plus 100mg Serophene®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Clomiphencitrat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 IU Merional® plus 100mg Serophene®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>450 IU Merional® plus Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 IU Merional® plus Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Clomiphencitrat</intervention_name>
    <description>100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).</description>
    <arm_group_label>High Dose Clomiphencitrat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Clomiphencitrat</intervention_name>
    <description>100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).</description>
    <arm_group_label>Low Dose Clomiphencitrat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Placebo</intervention_name>
    <description>Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).</description>
    <arm_group_label>High Dose Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Placebo</intervention_name>
    <description>Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).</description>
    <arm_group_label>Low Dose Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: &gt;18 years &lt; 43 years&#xD;
&#xD;
          -  BMI: ≥ 18 ≤ 32 kg/m2&#xD;
&#xD;
          -  Poor responder as defined by ESHRE working group&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 und &gt; 43 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Uterine conditions interfering with endometrial proliferation and embryo implantation&#xD;
             (submucous fibroids or polyps)&#xD;
&#xD;
          -  Women diagnosed with PCOS according to the Rotterdam criteria&#xD;
&#xD;
          -  Hyperprolactinaemia - untreated&#xD;
&#xD;
          -  Both ovaries not accessible transvaginally for oocyte pick up&#xD;
&#xD;
          -  Ovarian cysts of unclear dignity&#xD;
&#xD;
          -  Evidence of hydrosalpinx on ultrasound&#xD;
&#xD;
          -  Clinically significant severe systemic disease that are incompatible with pregnancy&#xD;
&#xD;
          -  Known or suspected hypersensitivity to the active substances (gonadotrophins,&#xD;
             ganirelix, progesterone, clomiphencitrate)&#xD;
&#xD;
          -  Untreated thyroid or adrenal disorders&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Severe renal or hepatic dysfunction&#xD;
&#xD;
          -  Necessity to take medication that could influence ovarian stimulation&#xD;
&#xD;
          -  History of OHSS in prior IVF cycle&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca E Moffat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Women's Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>female infertility</keyword>
  <keyword>poor ovarian response</keyword>
  <keyword>controlled ovarian hyperstimulation</keyword>
  <keyword>IVF</keyword>
  <keyword>Antagonist protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

